FDA Grants Final Approval For Lamisil Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis oral nail fungal treatment had annual sales of $685 million.
You may also be interested in...
Novartis Digs Deeper Into Lamisil DTC Campaign With National Tour
The centerpiece of a 23-city, consumer education campaign promoting foot health is a recreational vehicle featuring "Digger," the animated dermatophyte character seen in Lamisil direct-to-consumer advertising.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.